Guzdek Barbara, Fołta Kaja, Staniek Natalia, Stolarczyk Magdalena, Krukiewicz Katarzyna
Department of Physical Chemistry and Technology of Polymers, Silesian University of Technology, M. Strzody 9, 44-100 Gliwice, Poland.
Chemistry Students Research Society, Faculty of Chemistry, Silesian University of Technology, M. Strzody 9, 44-100 Gliwice, Poland.
Int J Mol Sci. 2025 Jul 6;26(13):6513. doi: 10.3390/ijms26136513.
Being one of the most aggressive primary brain tumors, glioblastoma multiforme (GBM) is known from the median survivals of just 15 months following diagnosis. Conventional treatments, including surgical resection, radiotherapy, and chemotherapy, have limited efficiency due to the invasive nature of glioma cells and the presence of a blood-brain barrier. Therefore, adjuvant therapy in the form of a localized delivery of chemotherapeutic agents is indispensable to increase the chances of patients. Among a variety of advanced drug carriers, collagen has recently emerged as an excellent choice for regional chemotherapy, mainly due to its biocompatibility, biodegradability, weak antigenicity, biomimetics, and well-known safety profile, as well as its native presence in the extracellular matrix of the central nervous system. The aim of this paper is to highlight the most recent studies describing the application of collagen as a drug carrier able to provide an extended delivery of chemotherapeutic agents directly to the GBM site, and to provide exciting opportunities for its future applications.
多形性胶质母细胞瘤（GBM）是最具侵袭性的原发性脑肿瘤之一，其确诊后的中位生存期仅为15个月。包括手术切除、放疗和化疗在内的传统治疗方法，由于胶质瘤细胞的侵袭性和血脑屏障的存在，效率有限。因此，以局部递送化疗药物的形式进行辅助治疗对于增加患者的生存机会是必不可少的。在各种先进的药物载体中，胶原蛋白最近已成为区域化疗的极佳选择，这主要归功于其生物相容性、可生物降解性、弱抗原性、仿生学特性、众所周知的安全性，以及它在中枢神经系统细胞外基质中的天然存在。本文的目的是突出描述胶原蛋白作为一种能够将化疗药物直接递送至GBM部位并实现延长释放的药物载体的最新研究，并为其未来应用提供令人兴奋的机会。
